Skip to content

Repair

All peptides
Blend

Wolverine

Also known as: Wolverine blend, BPC-157 / TB-500, BPC-157 + TB-500

The most common soft-tissue repair pairing — angiogenesis plus actin-driven cell migration. Co-injectable because the two are pH-compatible; the evidence remains preclinical.

Reviewed 2026-05-27

What it does

Wolverine pairs BPC-157 with TB-500 in a single fixed-ratio vial. BPC-157 contributes angiogenesis (VEGFR2/eNOS upregulation), fibroblast proliferation, collagen synthesis, and growth-hormone-receptor upregulation in tendon fibroblasts. TB-500 contributes G-actin sequestration that drives cell migration and wound contraction, broad anti-inflammatory cytokine modulation, and endothelial repair. They sit on parallel rather than redundant pathways, which is the rationale for combining them; the guide notes the two are pH-compatible, which is precisely why the pre-mixed blend exists.

Used for

Dose

Dose
500 mcg · 7 days/week (15 units of a 10/10 mg vial = 500 mcg of each)
When
FlexibleNo meaningful diurnal effect documented. Morning fasted or split AM/PM is common; for acute injury, dosing near the site matters more than time of day.
How long
2 months on / 1 month off
Site
subcutaneous, systemic or near the injury site
Food
any

Need exact volumes? Open the peptide calculator →

⚠ Caution

  • Active malignancy (theoretical angiogenesis/cell-migration concern — applies to both BPC-157 and TB-500)
  • Pregnancy and breastfeeding (no human safety data for either component)
  • Active sepsis (avoid TB-500 — immunomodulatory)
  • Competitive athletes — both BPC-157 and TB-500 are on the WADA prohibited list
  • Hypersensitivity to peptide formulations or excipients
  • Long-term continuous use lacks human safety data

Will it work for me?

Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.

Blood markers
  • Tier 2 — Human observationalhs-CRP / ESR↓· 6–12 weeksInflammation overlay, not a direct action marker.
Functional & psychometric
  • Tier 3 — Animal / in vitroRegion-specific function score (DASH / KOOS / ODI)↑· 6–12 weeksSelf-administered functional tracking is the practical default.
  • Tier 3 — Animal / in vitroPain scale (VAS / NPRS)↓· 2–4 weeks

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Cycling

2 months on, 1 month off.

Mild–moderate soft-tissue injury often resolves in 2–4 weeks; severe or post-op cases may run longer.

Related peptides

What's in this blend

  • BPC-15710 mg/vial· 50%angiogenesis, collagen synthesis, GHR upregulation
  • TB-50010 mg/vial· 50%actin sequestration, cell migration, anti-inflammatory
Reconstitution & storage
VialBAC waterConcentrationShelf life
20 mg3 mL500 mcg / 500 mcg per 15 units (10/10 mg blend)20 days

Standard blend vial is 10 mg BPC-157 + 10 mg TB-500. Reconstitute a 10/10 mg vial with 3 mL BAC water for 500 mcg / 500 mcg per 15 units; the vial lasts ~20 days at 15 units/day. For acute injury, inject near the affected area when anatomically feasible.

Storage. Lyophilized: refrigerate, stable 2+ years. Reconstituted: refrigerate 2–8 °C, use within ~20 days.

Open the peptide calculator →

Nasal delivery

Not suitable for nasal delivery. No established nasal protocol for the blend; TB-500's systemic tissue-repair action requires SQ delivery.

Monitoring & questions

Reported side effects
  • Injection site reactions
  • Mild fatigue reported anecdotally (BPC-157)
  • Headache
  • No long-term human safety data for the combination — flag explicitly
Biomarkers Juno tracks

Reference

How it works

Two complementary repair mechanisms in one injection. BPC-157 drives new vessel formation and collagen deposition at the injury site; TB-500 mobilizes cells into that site and damps the inflammatory cytokine response. The combination is used clinically in performance and recovery medicine, but combination-specific controlled human data does not exist — the evidence base is the two individual peptides' preclinical literature.

EvidenceTier 3 — Animal / in vitro

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Musculoskeletal soft-tissue injury recovery (muscle, tendon, ligament)

Tier 3high confidence

Rationale rests on the components' preclinical work: BPC-157 accelerates Achilles tendon and MCL repair in rats (Sikiric 2009) and TB-500/Thymosin β4 drives cell migration and re-epithelialization (Goldstein 2012). No controlled human trial of the combination exists.

Sikiric P et al. 1993Goldstein AL et al. 2012

Soft-tissue injury with significant inflammatory component

Tier 3high confidence

TB-500 adds broad anti-inflammatory cytokine modulation on top of BPC-157's cytoprotection. Mechanistically plausible and consistent across animal models; no human combination RCT.

Goldstein AL et al. 2012

Post-operative / athletic off-season recovery

Tier 3medium confidence

Used in recovery medicine for over a decade per the guide, but combination-specific clinical trial data is absent — evidence is extrapolated from individual-peptide preclinical models.

Sikiric P et al. 1993
Citations (2)
  1. [1]
    A new gastric juice peptide, BPC: stomach-stress-organoprotection hypothesis (and BPC-157 tendon/ligament repair work)
    Sikiric P, Petek M, Rucman R, et al. · Journal of Physiology Paris · 1993
    BPC-157 preclinical tissue-repair anchor for the blend's Tier 3 musculoskeletal indications.
    View source
  2. [2]
    Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
    Goldstein AL, Hannappel E, Sosne G, Kleinman HK · Expert Opinion on Biological Therapy · 2012
    TB-500/Thymosin β4 cell-migration and anti-inflammatory anchor; the guide's named TB-500 reference for the Wolverine blend.
    View source